Company intelligence / Profile preview
Origenis GmbH
- Ownership
- Private
- Employees
- ~30
- Development stage
- Preclinical
Overview
Origenis has developed a robust AI-driven platform for small molecule drug discovery with a focus on neurodegenerative and neuroinflammatory diseases. Its lead programs have been spun out into Neuron23 Inc., which has raised over $113 million to advance these assets toward clinical trials. The company continues to innovate in CNS, oncology, antiviral, and ophthalmology pipelines but does not yet have late-stage or commercialized products.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- small molecules
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Origenis GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Origenis GmbH.